menu_open Columnists
Luke Mcdonagh

Luke Mcdonagh

Financial Times

We use cookies to provide some features and experiences in QOSHE

More information  .  Close

How Novo Nordisk failed to protect its GLP-1 patent

Traditional intellectual property tools have proved insufficient against pharmacy compounders producing weight-loss drugs

02.09.2025 6

Financial Times

Luke Mcdonagh